Evidence map›Paper›PMID 20138243›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2010

Uptake and distribution of fullerenes in human mast cells.

Anthony Dellinger, Zhiguo Zhou, Sarah K Norton, Robert Lenk, Daniel Conrad, Christopher L Kepley

Open access · greenAbstract read
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Effects of Aqueous Dispersions of CInternational journal of molecular sciences · 2021
    Article
  4. Article
  5. Article
  6. Influence of physicochemical properties of silver nanoparticles on mast cell activation and degranulation.Toxicology in vitro : an international journal published in association with BIBRA · 2015
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anthony DellingerLuna Innovations Inc., Nanoworks Division, Danville, Virginia 24541, USA.
Zhiguo Zhou
Sarah K Norton
Robert Lenk
Daniel Conrad
Christopher L Kepley
Luna Innovations (United States) · USVirginia Commonwealth University · US

Funding

The Effect of Lyn Deficiency on Mast Cell Activation and Inflammatory Disease ProU19AI077435 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI CONRAD, DANIEL H · 2008 to 2012
$7.7M
STRUCTURE/FUNCTION OF THE LYMPHOCYTE FCE RECEPTORR01AI018697 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI MARTIN, REBECCA KELLEY · 1985 to 2018
$6.5M
Using Nanomaterials to Inhibit Mast Cell/Basophil-Associated DiseaseR01GM083274 · NIGMS · LUNA INNOVATIONS, INC. · PI KEPLEY, CHRIS L · 2008 to 2012
$1.5M
Prevention of Allergic Disease Using NanomaterialsR21ES015696 · NIEHS · LUNA INNOVATIONS, INC. · PI KEPLEY, CHRIS L · 2009 to 2010
$556k
Development of Novel Cholesteryl-Derivatized Endohedral Metallofullerenes for ImaR43HL087578 · NHLBI · LUNA INNOVATIONS, INC. · PI LENK, ROBERT · 2007 to 2008
$400k
NHLBI NIH HHS 1R43HL087578-01A1NHLBI NIH HHS R43 HL087578NIAID NIH HHS R01 AI018697NIAID NIH HHS R01AI018697-28NIAID NIH HHS U19 AI077435NIAID NIH HHS U19AI077435NIEHS NIH HHS R21 ES015696NIGMS NIH HHS 1R01GM083274-01NIGMS NIH HHS R01 GM083274
6 · The paper itself

Abstract

Fullerenes are carbon cages of variable size that can be derivatized with various side chain moieties resulting in compounds that are being developed into nanomedicines. Although fullerene use in several preclinical in vitro and in vivo models of disease has demonstrated their potential as diagnostic and therapeutic agents, little is known about how they enter cells, what organelles they target, and the time course for their cellular deposition. Fullerenes (C(70)) that have already been shown to be potent inhibitors of mast cell (MC)-mediated allergic inflammation were conjugated with Texas red (TR) and used in conjunction with confocal microscopy to determine mechanisms of uptake, the organelle localization, and the duration they can be detected in situ. We show that C(70)-TR are nonspecifically endocytosed into MCs, where they are shuttled throughout the cytoplasm, lysosomes, mitochondria, and into endoplasmic reticulum at different times. No nuclear or secretory granule localization was observed. The C(70)-TR remained detectable within cells at 1 week. These studies show that MCs endocytose fullerenes, where they are shuttled to organelles involved with calcium and reactive oxygen species production, which may explain their efficacy as cellular inhibitors. From the clinical editor: Fullerenes are carbon cages of variable size that have already been shown to be potent inhibitors of mast cell (MC)-mediated allergic inflammation. These were conjugated with Texas red (TR) and used in conjunction with confocal microscopy to determine mechanisms of uptake, the organelle localization, and duration, demonstrating that MCs endocytose fullerenes, which are shuttled to organelles involved with calcium and reactive oxygen species production. This intracellular trafficking may explain the efficacy of fullerenes as cellular inhibitors.

Indexed as

Cell NucleusEndocytosisFullerenesHumansMast CellsMicroscopy, ConfocalReactive Oxygen SpeciesFullerenesReactive Oxygen Species

Identifiers

PMID20138243
PMCPMC2888797
OpenAlexW2014717380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.